News & Events
2006 Press Releases
Eidogen-Sertanty licenses Target Informatics Platform to NCBI
San Diego, CA (August 21, 2006) - Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, announced today that they have licensed their Target Informatics Platform™ (TIP™) to the U.S. National Library of Medicine's National Center for Biotechnology Information (NCBI), based in Bethesda, MD.
Under the terms of the annual license, scientists at the NCBI will have access to the TIP structural knowledgebase as well as Eidogen-Sertanty's EVE Comparative Visualizer.
"We’re extremely pleased to be collaborating with the NCBI. They have developed a number of outstanding and widely used informatics platforms over the years, and I'm optimistic that our interaction will lead to new high impact advances," said Derek Debe, Eidogen-Sertanty's Chief Scientific Officer.
For more information, please contact:
About Eidogen-Sertanty, Inc.
Eidogen-Sertanty is a privately held company that is dedicated to helping scientists discover new medicines with innovative software technology and knowledgebases. To find out more about Eidogen-Sertanty please visit www.eidogen-sertanty.com.
The National Center for Biotechnology Information is part of the National Library of Medicine. Established in 1988 as a national resource for molecular biology information, NCBI creates public databases, conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information-all for the better understanding of molecular processes affecting human health and disease. NCBI is host to the GenBank nucleotide sequence database.